沙利度胺联合介入治疗中晚期肝癌疗效观察.pdfVIP

· 546· 中国肿瘤临床与康复2007年l2月第l4卷第6期 Chin J Clin Oncol Rehabil，December2007，V0l 14，No．6 临床应用 · 沙利度胺联合介入治疗中晚期肝癌疗效 观察 刘秀芳 张海 王炳胜 张建宇 (解放军第二五一医院肿瘤科，河北省张家口 075000) 【摘要】 目的 评价沙利度胺联合介入治疗中晚期肝癌的临床疗效。方法 89例中晚期肝癌 患者随机分为口服沙利度胺+肝动脉灌注栓塞化疗组(TLD+TACE组)和单纯肝动脉灌注栓塞化疗 组(TACE组)。结果 TLD+TACE组近期有效率、1年局控率分别为57．5％和65．0％，明显高于TA- CE组的34．5％和43．1％。不良反应以腹胀、便秘、头晕、嗜睡最常见，患者可耐受。结论 沙利度胺 联合介入治疗中晚期肝癌疗效明显，不良反应轻，具有一定的临床应用价值。 【关键词】 肝肿瘤； 沙利度胺；介入治疗 【中图分类号】R735．7；R730．53 【文献标识码】A 【文章编号】1005—8664(2007)06-0546-03 Efficacy of combined thalidomide and interventional therapy in treatment of advanced hepatocellular carcinoma LIUXiu-fang，ZHANGHai，WANGBing—sheng，et al (Department of Oncology，NO．251 Hospital ofPLA，Zhangjiakou，Hebei 075000，China) 【Abstract】 Objective To evaluate the clinical efficacy of thalidomide combined with interventional therapy in treatment of advanced hepatocellular carcinoma．Methods Eigllty—nine patients with advanced hepatocellular carcinoma were divided randomly into two groups：thalidomide(TLD)+transcatheter arterial chemoembolization(TACE)group and TACE group．Results The immediate effective rate and one year partial control rate of TLD+TACE group were 57．5％ and 65．0％ respectively．while those of the TACE group were 34．5％ and 43．1％ respectively．Thalidomide could cause abdominal distention，constipation，vet- tigo and somnolence，which could be tolerated by the patients．Conclusions Combined thalidomide and in— terventional therapy is more effective than TACE alone for the advanced hepatocellular carcinoma．Its adverse effects are tolerable，SO it has certain value for clinical application． 【Key words】 Liver neoplasms；Thalidomide；Interventional therapy 自2001年1月至2003年5月我们对98例中 年龄51岁。全组病例中甲胎蛋白(AFP)定量 ≥ 晚期原发性肝癌患者进行前瞻性随机分组研究，经 200 ng／ml者占58．2％(46／79)。其6例有少量腹 肝动脉化疗栓塞组(TACE)58例，经肝动脉化疗栓 水，24例有病理学诊断依据。瘤体最大11 c